XMADORY
Market cap92mUSD
Dec 20, Last price
1.53EUR
1D
-3.76%
1Q
-16.81%
Jan 2017
-64.73%
IPO
-61.77%
Name
Oryzon Genomics SA
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
8.42%
Rev. gr., 5y
29.46%
Revenues
14m
Net income
-3m
L-20.76%
CFO
-575k
L-68.88%
Earnings
Feb 24, 2025
Profile
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 14,192 | ||||
Cost of revenue | 6,480 | 2,382 | 3,199 | ||
Unusual Expense (Income) | |||||
NOPBT | 7,712 | (2,382) | (3,199) | ||
NOPBT Margin | 54.34% | ||||
Operating Taxes | (2,751) | (2,325) | (2,493) | ||
Tax Rate | |||||
NOPAT | 10,463 | (57) | (707) | ||
Net income | (3,353) -20.76% | (4,231) -9.72% | (4,687) 37.87% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (1,800) | ||||
BB yield | 1.57% | ||||
| Debt | |||||
Debt current | 11,939 | 10,380 | 3,424 | ||
Long-term debt | 3,529 | 7,160 | 10,347 | ||
Deferred revenue | |||||
Other long-term liabilities | 5,260 | 3,285 | 3,292 | ||
Net debt | 3,212 | (3,777) | (14,954) | ||
| Cash flow | |||||
Cash from operating activities | (575) | (1,848) | (3,626) | ||
CAPEX | (14,271) | (11,761) | |||
Cash from investing activities | (14,504) | (14,271) | (11,724) | ||
Cash from financing activities | 6,021 | 8,710 | 4,123 | ||
FCF | 10,593 | 14 | (745) | ||
| Balance | |||||
Cash | 12,257 | 21,317 | 28,725 | ||
Long term investments | |||||
Excess cash | 11,547 | 21,317 | 28,725 | ||
Stockholders' equity | (12,615) | (9,540) | (5,433) | ||
Invested Capital | 115,040 | 102,629 | 93,546 | ||
ROIC | 9.61% | ||||
ROCE | 7.53% | ||||
| EV | |||||
Common stock shares outstanding | 60,879 | 56,042 | 52,762 | ||
Price | 1.89 -23.87% | 2.48 -8.15% | 2.70 -22.86% | ||
Market cap | 114,940 -17.30% | 138,985 -2.44% | 142,456 -22.86% | ||
EV | 118,152 | 135,208 | 127,502 | ||
EBITDA | 7,865 | (2,216) | (3,055) | ||
EV/EBITDA | 15.02 | ||||
Interest | 1,894 | 1,119 | 456 | ||
Interest/NOPBT | 24.55% | ||||